iluvien 190 µg implant (applic.) i.vitr. applic.
alimera sciences europe ltd. - fluocinolonacetonide 0,19 mg - intravitreaal implant in applicator - 190 µg - fluocinolonacetonide 0.19 mg - fluocinolone acetonide
lipiodol ultra fluide 480 mg/ml inj. opl. i.arter./i.lymf. amp.
guerbet - papaver, zaad, gejodeerde olie vetzuur ethylester - oplossing voor injectie - 480 mg i/ml - jodium 2320 mg - ethyl esters of iodised fatty acids
micropaque 1 g/ml or./rect. opl.
guerbet - bariumsulfaat 100 g/100 ml - oplossing voor oraal/rectaal gebruik - 1 g/ml - bariumsulfaat 1000 mg/ml - barium sulfate without suspending agents
tvenforz 5 mg/ml oogdruppels opl. druppelfl.
alcon sa-nv - tetracaïnehydrochloride 5 mg/ml - oogdruppels, oplossing - 5 mg/ml - tetracaïnehydrochloride 5 mg/ml - tetracaine
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologica - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).